|
Press Releases |
|
 |
|
Monday, March 28, 2022 |
|
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 |
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 more info >> |
|
Tuesday, March 22, 2022 |
|
エーザイとバイオジェン、抗アミロイドβ(Aβ)プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会(AD/PD(TM) 2022)において発表 |
more info >> |
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 16, 2022 |
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
バイオジェン・インク(Nasdaq: BIIB、本社:米国マサチューセッツ州 ケンブリッジ、CEO:ミシェル・ヴォナッソス、以下 バイオジェン)とエーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、既存のアデュカヌマブ(米国の製品名ADUHELM)のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
Tuesday, March 15, 2022 |
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
Friday, March 11, 2022 |
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
Wednesday, March 9, 2022 |
|
Eisai Certified as the 2022 Health and Productivity Management Outstanding Organization (White 500) |
Eisai Co., Ltd. announced today that it has been certified as the Health and Productivity Management Outstanding Organization in the large enterprise category (White 500) by Japan's Ministry of Economy, Trade and Industry and the Nippon Kenko Kaigi. more info >> |
|
Monday, March 7, 2022 |
|
LENVIMA in Combination with KEYTRUDA Approved In Taiwan for the Treatment of Patients with Advanced Endometrial Carcinoma |
Eisai Co., Ltd. announced today that LENVIMA (generic name: lenvatinib mesylate), the multiple receptor tyrosine kinase inhibitor discovered by Eisai, in combination with Merck & Co., Inc., Kenilworth, N.J., U.S.A. more info >> |
|
エーザイ、「レンビマ(R)」「キイトルーダ(R)」との併用療法について、治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)は、このたび、自社創製のチロシンキナーゼ阻害剤「レンビマ(R)」(一般名:レンバチニブメシル酸塩)について、Merck & Co., Inc. Kenilworth, N.J., U.S.A.(北米以外ではMSD)の抗PD-1抗体「キイトルーダ(R)」(一般名:ペムブロリズマブ)との併用療法による治療ラインに関らず全身療法後に増悪した、根治的手術または放射線療法に不適応な進行性子宮内膜がんの適応で、台湾において承認を取得したことをお知らせします。 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00: JST
|
|
|
Alpaca Network Announces Launch of Modelz: The First Decentralized Exchange for AI Models
Jul 10, 2025 23:00 HKT/SGT
|
|
|
港交所單日「五連發」聯控體系貢獻近半
Jul 10, 2025 21:34 HKT/SGT
|
|
|
The 10th Quam IR Awards was Successfully Held
Jul 10, 2025 21:30 HKT/SGT
|
|
|
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
|
|
|
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
|
|
|
第十屆【華富卓越投資者關係大獎】頒獎典禮圓滿舉行
Jul 10, 2025 15:52 HKT/SGT
|
|
|
第十届【华富卓越投资者关系大奖】颁奖典礼圆满举行
Jul 10, 2025 15:09 HKT/SGT
|
|
|
港交所单日“五连发” 联控体系贡献近半
Jul 10, 2025 14:45 HKT/SGT
|
|
|
Tianci International: Discussing Strategic Opportunities for the Shipping and Logistics Industry to Integrate with Blockchain Technology and RWA
Jul 10, 2025 12:30 HKT/SGT
|
|
|
Tradable Bits Powers Fan Engagement for Rugby Australia's Hosting of the Qatar Airways British & Irish Lions Men's Tour 2025
Jul 10, 2025 07:30 HKT/SGT
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00: JST
|
|
|
Hola Prime Unveils 'Hola Prime Futures' with Industry-First 1-Hour Withdrawals, Expands Forex Offering with MT4 Integration
Jul 10, 2025 07:00 HKT/SGT
|
|
|
SAPPE's Female CEO Takes the World Stage at the Global Summit of Women 2025 in Berlin, Germany
Jul 9, 2025 22:00 HKT/SGT
|
|
|
康诺思腾自主创新研发的手术机器人 成功于英国启动首轮临床试验
Jul 9, 2025 20:35 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|